Vertical HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission.
Mother-to-Child HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women, both in developed and in developing countries. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir; they can be used as a combo, as tenofovir+emtricitabine for instance. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission in this context, justifying this retrospective study.
Study Type
OBSERVATIONAL
Enrollment
35
Hopital Lariboisiere
Paris, France
Hepatitis B sAg status in children born from HIV-Hepatitis B Virus co-infected women
Time frame: up to 10 years (expected average: 5 years)
Antibodies (Ab) against Hepatitis B core antigen in children
Time frame: up to 10 years (expected average: 5 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.